Abstract
Aim: Chronic kidney disease is a critical condition with considerable public health implications. It affects a significant proportion of the general population and when progressive, has an increasing influence on morbidity and mortality. The main purpose of this study was to explore the distribution and trends of renal replacement therapy and vascular access practice patterns among Saskatchewan end stage renal disease patients. Material and Method: This is a registry-based retrospective observational study. Prevalence of patient’s on renal replacement therapy in the Canadian Organ Replacement Register who has information for renal replacement therapy from 2006 to 2016 in the province of Saskatchewan. The composite of demographics, mortality, type of renal replacement therapy, type of vascular access and important blood markers ranges were recorded among both haemodialysis and peritoneal dialysis patients. Results: From 2006 through 2016, a total of 2103 patients with mean age of 69.52±13.2 initiated renal replacement therapy in Saskatchewan. Among those patients, over half of the patients were female (62%). Majority of the patients were Caucasians and Aboriginals. Nearly two third of them were overweight and obese. Less than half developed end stage renal diseases secondary to diabetes and 14.9% had a primary diagnosis of glomerulonephritis. At the end of 2015, prevalence of end-stage kidney disease patients was 1330 in the Saskatchewan. During 2006 to 2016, 72.3% received haemodialysis, 22.8% received peritoneal dialysis, and, catheter was the most frequently used dialysis access method (64.6%). Conclusion: An increasing number of patients with advanced renal disease are being initiated on long-term dialysis every year. Haemodialysis and peritoneal dialysis are the two main types of dialysis provided under renal care programs. Alarmingly, in Saskatchewan, catheter was the most frequently used dialysis access method. Keywords: End Stage Renal Disease; Renal Replacement Therapy; Vascular Access; Saskatchewan.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.